lanreotide acetate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
lanreotide acetate: clinical details
Prescribing considerations
- Confirm that tumour type, site, grade and disease setting match the licensed neuroendocrine-tumour population.
- Assess gallbladder, glucose and cardiovascular risk before treatment.
- Use caution with existing bradycardia, diabetes, gallbladder disease or symptoms suggesting pancreatic exocrine insufficiency.
- Ensure injection training and competency before patient or carer administration.
- Safety and efficacy have not been established in children and adolescents.
Contraindications and cautions
- Hypersensitivity to lanreotide, somatostatin, related peptides or an excipient.
Monitoring
- Clinical response and condition-specific biochemical or imaging markers.
- Blood glucose after initiation or treatment changes; review glucose-lowering therapy where necessary.
- Gallbladder imaging before prolonged treatment and periodically thereafter.
- Thyroid function when clinically indicated, particularly in acromegaly.
- Heart rate in patients with cardiac disease or bradycardia risk.
- Pituitary tumour volume in acromegaly.
- Investigate steatorrhoea, persistent loose stools, bloating or weight loss for pancreatic exocrine insufficiency.
Clinical pharmacology
Lanreotide is an octapeptide somatostatin analogue with greatest affinity for SSTR2 and SSTR5. Its supersaturated semi-solid formulation provides sustained release after deep subcutaneous administration.
Formulation and product differences
- Ready-to-use, white to pale-yellow semi-solid solution in a single-use pre-filled syringe.
- The selected product has an attached needle and automatic safety system.
- It contains water for injection and glacial acetic acid for pH adjustment.
lanreotide acetate preparations and strengths
Injection
Route: Parenteral
Strengths: 60 mg, 90 mg, 120 mg
lanreotide acetate interactions
Tell the prescribing team about all medicines, particularly those affecting glucose or heart rate and medicines requiring close blood-level control.
Ciclosporin
Lanreotide may reduce intestinal absorption and ciclosporin exposure, requiring blood-level monitoring and possible adjustment.
Insulin and other glucose-lowering medicines
Lanreotide can raise or lower blood glucose, so closer monitoring and treatment adjustment may be required.
Beta blockers and other heart-rate-lowering medicines
The combined effect may slow the heart rate further.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.